

The use of topical products to manage an atopic dermatitis relapse in a Jack Russell Terrier



Pierre-Marie Cadot, DVM
CES Dermatology
SeineVet Clinic
Rouen & Boos, France

History


> Jazzie, a 4-year-old female Jack Russell Terrier weighing 7.4 kgs, was diagnosed with atopic dermatitis when she was 3 years old after repeated relapses of pododermatitis and erythema on the flanks. Allergen-specific IgE serological (ASIS) tests revealed that Jazzie had a sensitivity to mites. Desensitization led to a decrease in frequency and intensity of the relapses for over a year. Desensitization was then replaced by injections of Lokivetmab 10 mg every three months to control the clinical signs. Parasite preventatives were given every three months with fluralaner tablets, and she was fed a hypoallergenic diet.

Clinical examination

- > Jazzie was in good general condition.
- > She presented with pruritus on the legs and face. Erythematous lesions were noticed on the external aspect of the ears, facial skin folds, interdigital spaces, flanks, and inguinal region. The CADESI-04 score at inclusion was 22/180 (mild) with severe pruritus (pruritus score: 7.1/10 on a visual analogue scale). No secondary infection was detected.
- > **Diagnosis: relapse of atopic dermatitis with erythema and severe pruritus.**

Management of the case

- > The aim was to repair the altered skin barrier and help calm the itch. A topical product is the first choice for this as the ingredients are applied directly to the target organ. A topical protocol with one DOUXO® S3 CALM Shampoo followed by DOUXO® S3 CALM Mousse applications every 48-72 hours for 3 weeks was prescribed. Lokivetmab injections were discontinued 6 months before inclusion.



Shampoo application



Mousse (leave-on) application

Results

- > Seven days after the first visit, an improvement in both the pruritus and skin health were noticed. The pruritus decreased to “very mild” according to the pet owner with a pruritus score of 2.1/10 (**70% improvement compared to D0**). The skin health had quickly improved with a **CADESI-04** decrease from 22 to 7 (68% decrease), going below the target threshold of 10/180 (dogs are considered to be comfortable when a score is under 10).

- › After 21 days, the pruritus was still considered as very mild with a pruritus score of 2.8/10 (61% improvement compared to D0), and CADESI-04 score was 61/180. This represented **an improvement of 73%** of the initial score.
- › Jazzie's owner was happy and satisfied with the protocol, the simplicity of use, and the performance.

She emphasized how easy the mousse was to use. She was also very pleased with the odor and texture of both shampoo and mousse.

- › **At the end of the protocol, Jazzie was considered to be in remission.**

› Before



› After 3 weeks



After three weeks, the CADESI-04 score had decreased by 73% and the pruritus score by 61%. On the right axilla, erythema and alopecia had improved.



Discussion - Mousse ensured better compliance for a busy home owner

- > Pet skin care can be time-consuming for owners, especially in cases of chronic skin conditions. A study carried out in 2010 showed that 32% of pet owners with an atopic dog felt that their dog's treatment was a burden¹. So, managing atopic dermatitis requires the use of products that are easy to apply and, where possible, are time-sparing.
- > Mousses are quick to use and allow the owner to spend more quality time with their pet. This encourages owner compliance. In three studies involving atopic dogs with relapses, the protocol combining one shampoo with subsequent mousses every 48-72 hours for three weeks was considered practical by 96% of pet owners².
- > Nowadays, people are very concerned about products they use. Pet owners absolutely need to feel confident the products are safe for their pet and the owners who apply the products, and especially in case of long-term use. They want to trust their brand and be sure it does not contain any controversial ingredients. The DOUXO® S3 CALM range avoids controversial ingredients and was tested in pets in acute conditions of exposure³ (increased quantity and frequency) to guarantee a high level of safety.



Key points

The results were excellent on both skin health and pruritus after just 7 days of application. The prescribing veterinarian emphasized that the mousse was a big plus as it allowed for improved hydration of the skin. The higher concentration of OPHYTRIUM™ in DOUXO® S3 CALM proved to limit the water loss⁴ that is observed in patients with atopic dermatitis. OPHYTRIUM™ has simultaneous action on the three skin barriers by strengthening the physical barrier⁴, restoring the balance of the protective microbial flora⁵ and soothing the skin.

Jazzie's owner was really satisfied with the protocol, both from a practicality and performance point of view, and with the characteristics of the products in terms of odor and texture. This, together with the pleasant application of the mousse, encourages compliance which is key in the management of chronic disorders.

As product safety is a major concern of pet owner's, it is crucial that the products are safe for pets and their families. The formulation scientists at Ceva Animal Health used only essential ingredients in the range to promote a high level of safety for both pets and their owners.

1. Linek, M., Favrot, C. (2010). Impact of canine atopic dermatitis on the health-related quality of life of affected dogs and quality of life of their owners. *Veterinary Dermatology*, 21:456-462.
2. Internal data, clinical cases (n=51)
3. Kolasa, E., Ferrer, L., Nejar, G., et al. (2019). Tolerance Assessment of two new Ophytrium-containing Topical Products Intended for Dogs with Sensitive Skin. *Proceedings of the 2019 SCIVAC Dermatology Congress*. Arezzo, Italy.
4. Ollivier, E., Zemirline, C., Amalric, N., et al. (2020). Efficacy of the ingredient A97614A1 in a model of reconstructed human epidermis stressed by cytokines. *Proceedings of the 62nd BSAVA Congress*, Birmingham, UK.
5. Ollivier, E., Zemirline, C., Marchand, L., et al. (2019). Effect of the ingredient A97614A1 on the adhesion and biofilm formation of *Staphylococcus pseudintermedius* in a model of reconstructed canine epidermis. *Proceedings of the 62nd BSAVA Congress*, Birmingham.

